In our study, trastuzumab enhanced NK cell degranulation much more vigorously against HER2-amplified targets compared to non-amplified targets in vitro, and it did not enhance NK cell functions against non-amplified primary breast cancer cells, suggesting that the HER2 expression level is important for the potential of the ADCC response. This evidence concerns the gene ERBB2 and breast carcinoma.